Non-Small Cell Lung Cancer Market to Surpass 76.33 Billion by 2030 Drives Due to Rising Incidence of Non-Small Cell Lung Cancer Diagnoses

SkyQuest projects that the non-small cell lung cancer market will attain a value of USD 76.33 billion by 2030, with a CAGR of 13.9% over the forecast period (2023-2030). Several vital factors further bolster the growth trajectory of the non-small cell lung cancer treatments market. One of these is the rising incidence of non-small cell lung cancer diagnoses across diverse regions in developed and developing areas. This growing prevalence underlines the pressing need for effective treatments, driving the demand for therapeutic solutions.

Westford, USA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest, the trajectory of the non-small cell lung cancer market is poised for advancement, propelled by a noteworthy trend – the escalating endorsement of innovative drugs by regulatory authorities to treat non-small cell lung cancer.

Browse in-depth TOC on the "Non-Small Cell Lung Cancer Market”

  • Pages - 165
  • Tables - 36
  • Figures – 74

Get sample copy of this report:

Integrating immune checkpoint inhibitors (ICIs) as a front-line treatment approach stands out as a principal catalyst propelling the growth of non-small cell lung cancer market revenue. The prevalence of non-small cell lung cancer (NSCLC), which constitutes 80 to 85 per cent of global lung cancer cases, underscores the urgency for innovative therapeutic strategies.

Prominent Players in Non-Small Cell Lung Cancer Market

  • Roche
  • AstraZeneca
  • Merck & Co.
  • Bristol-Myers Squibb
  • Pfizer Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Celgene Corporation
  • Boehringer Ingelheim
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen Inc.
  • Ipsen S.A.
  • Eisai Co., Ltd.
  • Taiho Oncology, Inc.
  • Gilead Sciences, Inc.

Browse summary of the report and Complete Table of Contents (ToC):

Targeted Therapy Segment is Expected to Grow the Market Due to Growing Significance Of Tailored Treatment Approaches

Targeted therapy segment asserted its dominance within the global non-small cell lung cancer market, commanding a substantial share exceeding 51%. This prominent position underscores the growing significance of tailored treatment approaches. Targeted therapy, a specialized treatment modality, involves using medications or specific chemical agents designed to target and precisely combat particular cancer cells.

The market in North America demonstrated its dominance in the non-small cell lung cancer market by generating a substantial revenue of USD 5.6 billion. This impressive financial achievement underscored the region's pivotal role in advancing treatments for this challenging medical condition.

Adenocarcinoma Segment is Expected to Dominate the Market Due to Substantial Patient Population

Adenocarcinoma segment asserted its dominance in the non-small cell lung cancer market, securing a significant share. This was primarily attributed to the substantial patient population afflicted by adenocarcinoma and the vast array of therapeutic options accessible for addressing this condition.

Regional markets in the Asia-Pacific are poised to exhibit the most rapid growth rate non-small cell lung cancer market. This projection is attributed to several compelling factors, chief among them being the escalating investments directed towards bolstering regional healthcare infrastructure.

A comprehensive analysis of the major players in the non-small cell lung cancer market has been recently conducted in a report. The report encompasses various aspects, including collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavours to develop innovative solutions to cater to the growing demand.

Key Developments in the Non-Small Cell Lung Cancer Market

  • In 2022, the Food and Drug Administration (FDA) granted formal approval to capmatinib, marketed under the name Tabrecta by Novartis Pharmaceuticals Corp. This approval holds profound implications for adult patients who have metastatic non-small cell lung cancer (NSCLC) who exhibit tumors bearing a mutation linked to mesenchymal-epithelial transition (MET) exon 14 skipping. To identify this specific genetic alteration, the FDA-approved diagnostic test is employed. This regulatory milestone marks a pivotal advancement in addressing a particular subset of NSCLC cases with tailored precision.
  • In 2022, a significant collaboration between Regeneron and BioNTech took a notable step forward. This collaborative agreement expanded its scope to encompass the development of a combination therapy involving Libtayo and FixVac (cemiplimab). This strategic partnership underscores the dedication to innovative therapeutic approaches, with a specific focus on addressing advanced non-small cell lung cancer (NSCLC).

Speak to Analyst for your custom requirements:

Key Questions Answered in Non-Small Cell Lung Cancer Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • List the top companies in the market and explain how they have achieved their positions of influence.


  • In what ways do regional trends and patterns differ within the global market, and how these differences shape the market's future growth?

Related Reports in SkyQuest’s Library:

Global Sustainable Footwear Market

Global Dye Sublimated Apparel Market

Global Functional Apparel Market

Global Men’s Swimwear Market

Global Snow Sports Apparel Market 

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.


1 Apache Way, Westford, Massachusetts 01886


USA (+1) 617-230-0741


LinkedIn Facebook Twitter